Immediate Effects of Different Stretching Methods for Pectoralis Minor Muscle

March 6, 2024 updated by: Tuğçe Çoban, Gazi University

Comparison of Immediate Effects of Different Stretching Methods for Pectoralis Minor Muscle on Scapula Position, Pectoralis Minor Muscle Length and Scapular Muscle Activation in Individuals With Shoulder Protraction

The aim of our study is to compare the effects of different stretching methods for the pectoralis minor (PM) muscle on scapula position, PM muscle length and scapular muscle activation in individuals with shoulder protraction. Unilateral corner stretching, manual stretching and proprioceptive neuromuscular facilitation (PNF) stretching methods will be applied randomly, 2 days apart, to volunteer individuals who agree to participate in our study. Three different stretching methods (unilateral corner stretching, manual stretching and PNF stretching) will be applied to individuals randomly, 48 hours apart, and PM length, PM index, scapula upward rotation and EMG values will be recorded by a blind evaluator before and after the stretching application.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Our study will include individuals who volunteer to participate in the study, and informed consent will be obtained from the individuals. Shoulder protraction will be determined according to the measurement result of the distance between the posterolateral side of the acromion and the bed in the supine position of the individual. If the distance is 2.6 centimeters or more, it will be recorded as shoulder protraction posture. PM length, PM index, upward rotation angle of the scapula at 0°, 45°, 90° and 135° abduction, electromyographic (EMG) muscle activation of the upper trapezius, middle trapezius, lower trapezius and serratus anterior muscles will be evaluated by a blind evaluator before and after the stretching methods. Unilateral corner stretching, manual stretching and proprioceptive neuromuscular facilitation (PNF) stretching methods will be applied randomly, 48 hours apart. The order of Unilateral Corner Stretching, Manual Stretching and PNF Stretching methods to be applied to individuals will be assigned with the simple allocation using random allocation. SPSS (Statistical Package for Social Sciences) version 22.0 will be used to evaluate the data obtained from the study and create tables. The Shapiro-Wilk test will be used to determine the distribution of the data. Descriptive statistics of numerical variables with normal distribution will be indicated by X ± SD, descriptive statistics of numerical variables without normal distribution will be indicated by median and (IQR), descriptive statistics of categorical variables will be indicated by frequency and percentage (%). Paired Sample T test will be used for intra-group comparison of normally distributed data and Wilcoxon test will be used for intra-group comparison of non-normally distributed data. The one-way repeated measures analysis of variance (ANOVA) will be performed to compare the three groups. The statistical significance level will be set at p<0.05 and a post-hoc multiple comparisons test with Bonferroni correction will be performed.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
25

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Turkey
    • Çankaya
      • Ankara, Çankaya, Turkey, 06490
        • Recruiting
        • Gazi University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Having a shoulder protraction posture
  • Not having had a shoulder surgery before
  • Agreeing to participate in the study

Exclusion Criteria:

  • Cervical or shoulder pain
  • Adhesive capsulitis
  • Thoracic outlet syndrome
  • Shoulder instability
  • Shoulder surgery history
  • Numbness or tingling in the upper extremity

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Group 3
PNF Stretching
Other: PNF Stretching
Individuals will be in a sitting position with their hands clasped behind the head. The PM muscle will be stretched in the direction of horizontal abduction by placing the physiotherapist's hands anterior to the elbows. Passive stretching will be continued for 10 seconds, followed by 6 seconds of maximum voluntary isometric contraction of the PM muscle. The procedure will be repeated four times with 30 seconds of rest.
Experimental: Group 1
Unilateral Corner Stretching
Other: Unilateral Corner Stretch
Individuals will be positioned in a standing position with the elbow in 90° flexion and the shoulder in 90° abduction, placing the palm on a flat surface. For stretching, individuals will be asked to increase shoulder horizontal abduction by rotating the trunk anteriorly and contralaterally. The position will be maintained for 30 seconds and will be repeated 4 times with a 30-second rest between repetitions.
Experimental: Group 2
Manual Stretching
Other: Manual Stretching
Individuals will be positioned supine with the shoulder in 90º abduction and external rotation and the elbow in 90º flexion. Stretching will be applied by the physiotherapist from just distal to the elbow in the direction of horizontal abduction of the shoulder. The position will be maintained for 30 seconds and will be repeated 4 times with a 30-second rest between repetitions.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Pectoralis Minor Length
Time Frame: Baseline
To measure the length of the pectoralis minor muscle, the distance between the caudal corner of the 4th rib and the inferomedial face of the coracoid process will be recorded with a tape measure.
Baseline
Pectoralis Minor Length
Time Frame: Immediately after intervention
To measure the length of the pectoralis minor muscle, the distance between the caudal corner of the 4th rib and the inferomedial face of the coracoid process will be recorded with a tape measure.
Immediately after intervention
Pectoralis Minor Index
Time Frame: Baseline
PM index will be recorded by calculating the ratio of the pectoralis minor length to the individual's height multiplied by 100.
Baseline
Pectoralis Minor Index
Time Frame: Immediately after intervention
PM index will be recorded by calculating the ratio of the pectoralis minor length to the individual's height multiplied by 100.
Immediately after intervention
Scapula Upward Rotation Measurement
Time Frame: Baseline
Individuals' scapula upward rotation measurement will be evaluated with an inclinometer in the resting position, 45º, 90º and 135º shoulder abduction positions. Three measurements will be taken with a 30-second rest interval and the average value will be calculated.
Baseline
Scapula Upward Rotation Measurement
Time Frame: Immediately after intervention
Individuals' scapula upward rotation measurement will be evaluated with an inclinometer in the resting position, 45º, 90º and 135º shoulder abduction positions. Three measurements will be taken with a 30-second rest interval and the average value will be calculated.
Immediately after intervention
EMG Analysis
Time Frame: Baseline
Individuals' upper trapezius, middle trapezius, lower trapezius and serratus anterior muscle activations will be evaluated using superficial EMG. Measurements will be taken from the dominant side.
Baseline
EMG Analysis
Time Frame: Immediately after intervention
Individuals' upper trapezius, middle trapezius, lower trapezius and serratus anterior muscle activations will be evaluated using superficial EMG. Measurements will be taken from the dominant side.
Immediately after intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Gazi University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Selda Başar, PhD, Gazi University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 11, 2023

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 3, 2024

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
September 4, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 6, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 6, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 13, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 13, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 6, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2024

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • E-77082166-302.08.01-639069

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rounded Shoulder Posture

Clinical Trials on Unilateral Corner Stretch

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings